Human FGF17 is a member of the broadly mitogenic FGF family, members of which have key roles in prenatal development, postnatal growth and tissue regeneration. FGF17 has been implicated in the organization and induction of the midbrain/hindbrain junction. It is also found in the developing skeleton, major arteries, heart, tail bud and hindgut, where it is often expressed just following FGF8 expression. While deletion of FGF17 does allow for viable mice, these mice demonstrate abnormalities in areas of the brain and demonstrate abnormal social behaviour. In humans abnormal patterns of FGF17 expression are associated with Dandy-Walker cerebellar malformation as well as a number of types of cancer. Human FGF17 shares 99% sequence similarity with the mouse and rat forms. Recombinant Human FGF17 is a 22.8 kDa heparin binding growth factor.
Alternative Names
Fibroblast growth factor 17
Quantity
1.0 mg
Regulatory
RUO
Source
E. coli
Host
Human
Endotoxin Level
<1.0 EU/μg of recombinant protein as determined by the LAL method
Weight
22.8 kDa
Format
Lyophilized PowderLyophilized from 0.2 μm filtered solution in PBS
Purity
>95% as determined by SDS-PAGE
Storage
The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity.